CN101133156A - 中国仓鼠凋亡相关基因 - Google Patents

中国仓鼠凋亡相关基因 Download PDF

Info

Publication number
CN101133156A
CN101133156A CNA2005800488118A CN200580048811A CN101133156A CN 101133156 A CN101133156 A CN 101133156A CN A2005800488118 A CNA2005800488118 A CN A2005800488118A CN 200580048811 A CN200580048811 A CN 200580048811A CN 101133156 A CN101133156 A CN 101133156A
Authority
CN
China
Prior art keywords
sequence
cell
seq
polypeptide
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800488118A
Other languages
English (en)
Chinese (zh)
Inventor
黄智宏
米兰达·G·S·亚普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN101133156A publication Critical patent/CN101133156A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800488118A 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因 Pending CN101133156A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64033304P 2004-12-30 2004-12-30
US60/640,333 2004-12-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2010102090324A Division CN101875957A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CN2010102090432A Division CN101875692A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因

Publications (1)

Publication Number Publication Date
CN101133156A true CN101133156A (zh) 2008-02-27

Family

ID=36615341

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2005800488118A Pending CN101133156A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CN2010102090432A Pending CN101875692A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CN2010102090324A Pending CN101875957A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2010102090432A Pending CN101875692A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CN2010102090324A Pending CN101875957A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因

Country Status (9)

Country Link
US (5) US7846894B2 (enExample)
EP (6) EP2298888A1 (enExample)
JP (1) JP5089400B2 (enExample)
KR (1) KR20070082597A (enExample)
CN (3) CN101133156A (enExample)
AU (1) AU2005322686B2 (enExample)
IL (1) IL183361A0 (enExample)
SG (1) SG158841A1 (enExample)
WO (1) WO2006071200A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825191B1 (en) 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2014068048A1 (en) * 2012-11-05 2014-05-08 Celonic Ag Expression system
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107630038A (zh) * 2017-09-15 2018-01-26 浙江大学 提高老年大鼠骨髓间充质干细胞移植后生存能力的方法
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
CN108359632A (zh) * 2018-03-30 2018-08-03 吉林冠界生物技术有限公司 Mdck细胞系、复制病毒的方法及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
EP0816497A3 (en) * 1996-06-26 1999-12-22 Smithkline Beecham Corporation Human requiem polypeptide for apoptosis
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue
US20040143111A1 (en) * 1997-04-17 2004-07-22 Incyte Corporation Novel apoptosis-associated protein
US6451759B1 (en) 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
US6683168B1 (en) 1998-04-21 2004-01-27 Boston Medical Center Corporation Genes and methods that modulate apoptosis
WO1999053743A2 (en) * 1998-04-21 1999-10-28 The Trustees Of Boston University Novel genes and methods that modulate apoptosis
US6015712A (en) * 1999-07-19 2000-01-18 Isis Pharmaceuticals Inc. Antisense modulation of FADD expression
AU7614600A (en) 1999-09-27 2001-04-30 Genentech Inc. Methods for making recombinant proteins using apoptosis inhibitors
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
US20040023385A1 (en) * 2002-08-05 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of requiem expression
US7326768B2 (en) * 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
CN1548054A (zh) * 2003-05-08 2004-11-24 陆爱丽 预防或治疗sars冠状病毒的药物

Also Published As

Publication number Publication date
CN101875957A (zh) 2010-11-03
EP2298889A1 (en) 2011-03-23
US20110129927A1 (en) 2011-06-02
US20110318316A1 (en) 2011-12-29
IL183361A0 (en) 2007-09-20
US20080295190A1 (en) 2008-11-27
AU2005322686B2 (en) 2012-01-19
WO2006071200A2 (en) 2006-07-06
EP2298887A1 (en) 2011-03-23
WO2006071200A3 (en) 2007-01-25
EP2298890A1 (en) 2011-03-23
JP2008526200A (ja) 2008-07-24
KR20070082597A (ko) 2007-08-21
EP2298888A1 (en) 2011-03-23
SG158841A1 (en) 2010-02-26
AU2005322686A1 (en) 2006-07-06
JP5089400B2 (ja) 2012-12-05
US20110318831A1 (en) 2011-12-29
US7846894B2 (en) 2010-12-07
CN101875692A (zh) 2010-11-03
EP1831366A2 (en) 2007-09-12
EP1997890A1 (en) 2008-12-03
US20110318317A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US7846894B2 (en) Chinese hamster apoptosis-related genes
US6046158A (en) Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
JP4112627B2 (ja) 新規ポリペプチド、新規ｄｎａおよび新規抗体
Holmgreen et al. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members
JPWO1998029544A1 (ja) 新規ポリペプチド、新規ｄｎａおよび新規抗体
US20090170165A1 (en) Method for recombinant production in cho cells
WO1998015624A9 (en) Galectin 8, 9, 10 and 10sv
US5922320A (en) Recombinant proCVF
US8193153B2 (en) Trophic factor for the treatment of retinal degenerative diseases
JP2001517943A (ja) ヒト膵炎関連タンパク質、ｐａｐ−２
US6194171B1 (en) Nucleic acids encoding ataxin-2 binding proteins
JP2001231578A (ja) Ｉｌ−１ファミリーに属する蛋白質
US20040081972A1 (en) Novel physiologically active peptide and use thereof
JP2002532056A (ja) ヒト輸送タンパク質相同体
Möröy et al. Regulators of life and death: the bcl-2 gene family
US20060084799A1 (en) Human cDNA clones comprising polynucleotides encoding polypeptides and methods of their use
JP4041913B2 (ja) 抗腫瘍タンパク質およびその遺伝子
JP3929744B2 (ja) 新規ポリぺプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
TWI278319B (en) VGF selective binding agents and methods of treating VGF-related disorders
Prabhakaran Fas-FasL expression and interactions in mouse tumor cell lines: Implications for tumor immune escape
JPWO2002010371A1 (ja) 新規な生理活性ペプチド及びその用途
WO2000040609A1 (fr) Nouvelle proteine
JP2002503110A (ja) 翻訳制御開始因子４ｅ−結合タンパク質
UA74529C2 (en) CASH (CASPASE HOMOLOGUE) WITH ôDEATH-EFFECTOR" DOMAIN, MODULATORS OF FAS-RECEPTOR FUNCTIONS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080227